Cargando…
VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19
BACKGROUND: Nirmatrelvir–ritonavir has been authorized for emergency use by many countries for the treatment of coronavirus disease 2019 (Covid-19). However, the supply falls short of the global demand, which creates a need for more options. VV116 is an oral antiviral agent with potent activity agai...
Autores principales: | Cao, Zhujun, Gao, Weiyi, Bao, Hong, Feng, Haiyan, Mei, Shuya, Chen, Peizhan, Gao, Yueqiu, Cui, Zhilei, Zhang, Qin, Meng, Xianmin, Gui, Honglian, Wang, Weijing, Jiang, Yimei, Song, Zijia, Shi, Yiqing, Sun, Jing, Zhang, Yifei, Xie, Qing, Xu, Yiping, Ning, Guang, Gao, Yuan, Zhao, Ren |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Massachusetts Medical Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812289/ https://www.ncbi.nlm.nih.gov/pubmed/36577095 http://dx.doi.org/10.1056/NEJMoa2208822 |
Ejemplares similares
-
Nirmatrelvir-ritonavir for COVID-19
por: McDonald, Emily G, et al.
Publicado: (2022) -
Nirmatrelvir and ritonavir for COVID-19
Publicado: (2022) -
Nirmatrelvir Plus Ritonavir: First Approval
por: Lamb, Yvette N.
Publicado: (2022) -
Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19
por: Lu, Jiayue, et al.
Publicado: (2023) -
Antiviral effect of azvudine and nirmatrelvir-ritonavir among hospitalized patients with COVID-19
por: Gao, Yuan, et al.
Publicado: (2023)